Brian Charles

- **INNOVATE Corp.'s** equity method investment, **MediBeacon Inc.**, has received full approval from the **National Medical Products Administration (NMPA)** in China for its **Lumitrace® (relmapirazin) injection**, completing the regulatory process for the **Transdermal GFR System (TGFR)**.  **[1006837_71ca0a5dda864d35b827cd70be9a27af_1]** 
- The **MediBeacon Transdermal GFR System (TGFR)**, a **first-in-kind product** for point-of-care kidney function assessment, is expected to be available for sale in **China before the end of the year**.  **[1006837_71ca0a5dda864d35b827cd70be9a27af_0]** **[1006837_71ca0a5dda864d35b827cd70be9a27af_1]** 
- This approval opens a **significant market opportunity** in China, where an estimated **11% of the 1.4 billion population suffers from Chronic Kidney Disease (CKD)**.  **[1006837_71ca0a5dda864d35b827cd70be9a27af_1]**

INNOVATE (VATE)